ICU Medical (ICUI) Issues FY 2018 Earnings Guidance

Share on StockTwits

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided EPS guidance of $8.45-8.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.60. ICU Medical also updated its FY18 guidance to $8.45-8.85 EPS.

Shares of ICUI stock opened at $232.01 on Friday. The company has a market cap of $5.31 billion, a PE ratio of 35.99 and a beta of 0.65. ICU Medical has a 1-year low of $196.33 and a 1-year high of $321.70.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, November 8th. The medical instruments supplier reported $1.85 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.34. The business had revenue of $327.20 million during the quarter, compared to the consensus estimate of $334.97 million. ICU Medical had a return on equity of 12.78% and a net margin of 5.93%. The business’s quarterly revenue was down 4.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 EPS. Research analysts anticipate that ICU Medical will post 7.6 earnings per share for the current year.

Several analysts recently commented on the company. ValuEngine cut ICU Medical from a strong-buy rating to a buy rating in a research report on Friday, August 3rd. Zacks Investment Research upgraded ICU Medical from a hold rating to a strong-buy rating and set a $337.00 price target for the company in a research report on Wednesday, August 15th. TheStreet upgraded ICU Medical from a c+ rating to a b+ rating in a research report on Monday, August 20th. Finally, BidaskClub cut ICU Medical from a strong-buy rating to a buy rating in a research report on Thursday, September 20th.

In related news, VP Thomas D. Mccall sold 11,133 shares of the business’s stock in a transaction that occurred on Friday, August 24th. The stock was sold at an average price of $302.56, for a total transaction of $3,368,400.48. Following the completion of the sale, the vice president now directly owns 3,018 shares in the company, valued at $913,126.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pfizer Inc sold 700,000 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $284.35, for a total value of $199,045,000.00. The disclosure for this sale can be found here. Insiders have sold 711,920 shares of company stock valued at $202,651,956 over the last quarter. 12.50% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://weekherald.com/2018/11/10/icu-medical-icui-issues-fy-2018-earnings-guidance.html.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Read More: Why does a company issue an IPO?

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply